Longeveron Inc. (LGVN) compared with its closest peers (PDSB, NRXP, RNXT, MTNB, IMUX). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
PDS Biotechnology, NRx Pharmaceuticals, RenovoRx, Matinas BioPharma, Immunic, Daré Bioscience, Relmada Therapeutics, Unicycive Therapeutics, 60 Degrees Pharmaceuticals and Shattuck Labs share Longeveron's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| PDS Biotechnology Corporation (PDSB) | $40.23M | — |
| NRx Pharmaceuticals, Inc. (NRXP) | $149.37M | -2.0 |
| RenovoRx, Inc. (RNXT) | $116.36M | — |
| Matinas BioPharma Holdings, Inc. (MTNB) | $1.21M | -0.3 |
| Immunic, Inc. (IMUX) | $194.16M | -0.9 |
| Daré Bioscience, Inc. (DARE) | $29.74M | -1.6 |
| Relmada Therapeutics, Inc. (RLMD) | $477.25M | -3.3 |
| Unicycive Therapeutics, Inc. (UNCY) | $138.97M | -3.4 |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $2.58M | -0.0 |
| Shattuck Labs, Inc. (STTK) | $529.86M | -5.2 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
LGVN overview · LGVN earnings · LGVN financials · LGVN KPIs · LGVN documents · LGVN ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.